Novo Nordisk
Novo Nordisk is a Danish multinational pharmaceutical company that specializes in diabetes care and hormone replacement therapies. Founded in 1923, the company is known for its innovative insulin products and GLP-1 receptor agonists, such as Ozempic, which are used for managing diabetes and aiding in weight loss. Novo Nordisk has a strong commitment to research and development, particularly in the fields of diabetes, obesity, and hemophilia.
Born on Sep 07, 1923 (102 years old)
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Romania | 1 | 7.00 | 0.09% | +0% | 19,237,691 | 17,331 | $250,000 | 225$ |
| Totals | 1 | 19,237,691 | 17,331 | $250,000 | 225$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Romania:
Novo Nordisk is working on a similar experimental treatment recently acquired from China.
7
France:
Novo Nordisk was in competition with Pfizer to acquire Metsera but ultimately lost the bid.
4
Denmark:
Novo Nordisk is competing with Pfizer and Metsera in the weight loss medication market.
5
Denmark:
Novo Nordisk's bid for Metsera is the second major deal the company is pursuing in October.
5
Denmark:
Novo Nordisk is facing significant changes in its board due to disagreements.
5
Denmark:
Novo Nordisk's stock is worth 39 percent less today than it was at the beginning of the year.
3
Denmark:
Novo Nordisk's weight loss medication is among those recommended by the World Health Organization.
8
Brazil:
Novo Nordisk requested the inclusion of semaglutide in the public health system.
6
Switzerland:
Novo Nordisk is a Danish insulin manufacturer that has faced challenges in meeting growth expectations.
5
Estonia:
Novo Nordisk is being sued by numerous individuals for serious side effects caused by its popular weight loss drug Ozempic.
2